Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

FTY720 ameliorates oxazolone colitis in mice by directly affecting T helper type 2 functions.

Daniel C, Sartory NA, Zahn N, Schmidt R, Geisslinger G, Radeke HH, Stein JM.

Mol Immunol. 2007 Jul;44(13):3305-16. Epub 2007 May 1.

PMID:
17475330
3.

Central nervous system-directed effects of FTY720 (fingolimod).

Miron VE, Schubart A, Antel JP.

J Neurol Sci. 2008 Nov 15;274(1-2):13-7. doi: 10.1016/j.jns.2008.06.031. Epub 2008 Aug 3. Review.

PMID:
18678377
4.

Ascomycete derivative to MS therapeutic: S1P receptor modulator FTY720.

Hiestand PC, Rausch M, Meier DP, Foster CA.

Prog Drug Res. 2008;66:361, 363-81. Review.

PMID:
18416311
5.

Homeostatic (IL-7) and effector (IL-17) cytokines as distinct but complementary target for an optimal therapeutic strategy in inflammatory bowel disease.

Kanai T, Nemoto Y, Kamada N, Totsuka T, Hisamatsu T, Watanabe M, Hibi T.

Curr Opin Gastroenterol. 2009 Jul;25(4):306-13. doi: 10.1097/MOG.0b013e32832bc627. Review.

PMID:
19448533
6.
7.
8.

Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.

Dev KK, Mullershausen F, Mattes H, Kuhn RR, Bilbe G, Hoyer D, Mir A.

Pharmacol Ther. 2008 Jan;117(1):77-93. Epub 2007 Sep 8. Review.

PMID:
17961662
9.

FTY720: A new kid on the block for transplant immunosuppression.

Aki FT, Kahan BD.

Expert Opin Biol Ther. 2003 Jul;3(4):665-81. Review.

PMID:
12831371
10.

Type I interferons and their therapeutic role in Th2-regulated inflammatory disorders.

Tilg H, Kaser A.

Expert Opin Biol Ther. 2004 Apr;4(4):469-81. Review.

PMID:
15102597
11.

FTY720 (fingolimod) for relapsing multiple sclerosis.

Horga A, Montalban X.

Expert Rev Neurother. 2008 May;8(5):699-714. doi: 10.1586/14737175.8.5.699. Review.

PMID:
18457527
12.

The FTY720 story.

Napoli KL.

Ther Drug Monit. 2000 Feb;22(1):47-51. Review.

PMID:
10688258
13.

FTY720: from bench to bedside.

Kahan BD.

Transplant Proc. 2004 Mar;36(2 Suppl):531S-543S. Review.

PMID:
15041402
14.

Defects in mucosal immunity leading to ulcerative colitis.

Targan SR, Karp LC.

Immunol Rev. 2005 Aug;206:296-305. Review.

PMID:
16048556
15.

Overview of FTY720 clinical pharmacokinetics and pharmacology.

Kovarik JM, Schmouder RL, Slade AJ.

Ther Drug Monit. 2004 Dec;26(6):585-7. Review.

PMID:
15570180
16.

Preclinical evaluation of a new immunosuppressive agent, FTY720.

Troncoso P, Kahan BD.

Clin Biochem. 1998 Jul;31(5):369-73. Review.

PMID:
9721436
17.

Cytokines in the pathogenesis of ulcerative colitis.

Bamias G, Kaltsa G, Ladas SD.

Discov Med. 2011 May;11(60):459-67. Review.

18.

The role of IL-13 and NK T cells in experimental and human ulcerative colitis.

Fuss IJ, Strober W.

Mucosal Immunol. 2008 Nov;1 Suppl 1:S31-3. doi: 10.1038/mi.2008.40. Review.

19.

Current perspectives on FTY720.

Martini S, Peters H, Böhler T, Budde K.

Expert Opin Investig Drugs. 2007 Apr;16(4):505-18. Review.

PMID:
17371198
20.

FTY720 (fingolimod) in renal transplantation.

Budde K, Schütz M, Glander P, Peters H, Waiser J, Liefeldt L, Neumayer HH, Böhler T.

Clin Transplant. 2006;20 Suppl 17:17-24. Review.

PMID:
17100697

Supplemental Content

Support Center